论文部分内容阅读
AIM:To construct a DNA vaccine encoding human alpha-fetoprotein(hAFP)/heat shock protein 70(HSP70),and tostudy its ability to induce specific CTL response and itsprotective effect against AFP-expressing tumor.METHODS:A DNA vaccine was constructed by combininghAFP gene with HSP70 gene.SP2/0 cells were stablytransfected with pBBS212-hAFP and pBBS212-hAFP/HSP70eukaryotic expression vectors.Mice were primed andboosted with DNA vaccine hAFP/HSP70 by intramuscularinjection,whereas plasmid with hAFP or HSP70 was usedas controls.ELISPOT and ELISA were used to detect IFN-γ-producing splenocytes and the level of serum anti-AFPantibody from immunized mice respectively.In vivo tumorchallenge was measured to assess the immune effect ofthe DNA vaccine.RESULTS:By DNA vaccine immunization,the results ofELISPOT and ELISA showed that the number of IFN-γ-producing splenocytes and the level of serum anti-AFPantibody were significantly higher in rhAFP/HSP70 groupthan in hAFP and empty plasmid groups(95.50±10.90IFN-γ spots/10~6 cells vs 23.60±11.80 IFN-γ spots/10~6 cells,7.17±4.24 IFN-γ spots/10~6 cells,P<0.01;126.50±8.22μg/mLvs 51.72±3.40 μg/mL,5.83±3.79 μg/mL,P<0.01).Thetumor volume in rhAFP/HSP70 group was significantly smallerthan that in pBBS212-hAFP and empty plasmid groups(37.41±7.34 mm~3 vs381.13±15.48 mm~3,817.51+16.25 mm~3,P<0.01).CONCLUSION:Sequential immunization with a recombinantDNA vaccine encoding AFP and heat shock protein70 couldgenerate effective AFP-specific T cell responses and inducedefinite antitumor effects on AFP-producing tumors,whichmay be suitable for some clinical testing as a vaccine forHCC.Wang XP,Liu GZ,Song AL,Li HY,Liu Y.Antitumor immunityinduced by DNA vaccine encoding alpha-fetoprotein/heat shockprotein 70.World J Gastroenterol 2004;10(21):3197-3200http://www.wjgnet.com/1007-9327/10/3197.asp
AIM: To construct a DNA vaccine encoding human alpha-fetoprotein (hAFP) / heat shock protein 70 (HSP70), and tostudy its ability to induce specific CTL response and its protein associated effect against AFP-expressing tumor. METHODS: A DNA vaccine was constructed by combininghAFP gene with HSP70 gene.SP2 / 0 cells were stablytransfected with pBBS212-hAFP and pBBS212-hAFP / HSP70eukaryotic expression vectors. Mice were primed and boosted with DNA vaccine hAFP / HSP70 by intramuscularinjection, in vitro with hAFP or HSP70 was usedas controls. ELISPOT and ELISA were used to detect IFN-γ-producing splenocytes and the level of serum anti-AFPantibody from immunized mice respectively. Vivo tumor challenge was measured to assess the immune effect of the DNA vaccine. Results: By DNA vaccine immunization, the results of ELISA and ELISA showed that the number of IFN-γ-producing splenocytes and the level of serum anti-AFPantimers were significantly higher in rhAFP / HSP70 groupthan in hAFP and empty plasmid groups (95.5 Γ ± spots / 10 ~ 6 cells, P <0.01; 126.50 ± 8.22 μg / mL vs 51.72 ± 3.40 μg / mL, 5.83 ± 3.79 μg / mL, P <0.01). The tumor volume in rhAFP / HSP70 group was significantly smallerthan that in pBSS1212-hAFP and empty plasmid groups (37.41 ± 7.34 mm 3 vs 381.13 ± 15.48 mm ~ 3,817.51 + 16.25 mm ~ 3, P <0.01) .CONCLUSION: Sequential immunization with a recombinant DNA vaccine encoding AFP and heat shock protein 70 couldgenerate effective AFP-specific T cell responses and inducedefinite antitumor effects on AFP-producing tumors, whichmay be suitable for some clinical testing as a vaccine for HCC. Wang XP, Liu GZ, Song AL, Li HY, Liu Y. Antitumor immunity induced by DNA vaccine encoding alpha-fetoprotein / heat shock protein 70. World J Gastroenterol 2004; 10 (21): 3197-3200 http: //www.wjgnet.com/1007-9327/10/3197.asp